NO126085B - - Google Patents
Download PDFInfo
- Publication number
- NO126085B NO126085B NO4341/70A NO434170A NO126085B NO 126085 B NO126085 B NO 126085B NO 4341/70 A NO4341/70 A NO 4341/70A NO 434170 A NO434170 A NO 434170A NO 126085 B NO126085 B NO 126085B
- Authority
- NO
- Norway
- Prior art keywords
- benzodiazepine
- parts
- phenyl
- chloro
- volume
- Prior art date
Links
- 238000006243 chemical reaction Methods 0.000 claims description 13
- -1 2- (4-substituted thiosemicarbazido)-1,4-benzodiazepine Chemical class 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 230000003635 deoxygenating effect Effects 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000005864 Sulphur Chemical group 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 38
- 239000013078 crystal Substances 0.000 description 27
- 238000002844 melting Methods 0.000 description 23
- 230000008018 melting Effects 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 238000001953 recrystallisation Methods 0.000 description 21
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 238000000921 elemental analysis Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 5
- GWSXDWFXNVOIIC-UHFFFAOYSA-N (7-chloro-5-phenyl-3h-1,4-benzodiazepin-2-yl)hydrazine Chemical compound N=1CC(NN)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 GWSXDWFXNVOIIC-UHFFFAOYSA-N 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- NWKYZYGOSPOKDY-UHFFFAOYSA-N n,n-dimethylformamide;pyridine Chemical compound CN(C)C=O.C1=CC=NC=C1 NWKYZYGOSPOKDY-UHFFFAOYSA-N 0.000 description 4
- BKXMIHOSZZYXDH-UHFFFAOYSA-N 8-chloro-6-phenyl-2,4-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-one Chemical compound C=1C(Cl)=CC=C(N2C(=O)NN=C2CN=2)C=1C=2C1=CC=CC=C1 BKXMIHOSZZYXDH-UHFFFAOYSA-N 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 229940117953 phenylisothiocyanate Drugs 0.000 description 3
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- LSNRYGYYRQVPAA-UHFFFAOYSA-N 1-[(7-chloro-5-phenyl-3H-1,4-benzodiazepin-2-yl)amino]-3-methylurea Chemical compound ClC=1C=CC2=C(C(=NCC(=N2)NNC(=O)NC)C2=CC=CC=C2)C1 LSNRYGYYRQVPAA-UHFFFAOYSA-N 0.000 description 2
- QQUIWIVTEWQHKA-UHFFFAOYSA-N 3h-1,4-benzodiazepine Chemical compound C1=NCC=NC2=CC=CC=C21 QQUIWIVTEWQHKA-UHFFFAOYSA-N 0.000 description 2
- CPDOVQULRSCNBK-UHFFFAOYSA-N 8-chloro-6-phenyl-2,4-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-1-thione Chemical compound C12=CC(Cl)=CC=C2N2C(S)=NN=C2CN=C1C1=CC=CC=C1 CPDOVQULRSCNBK-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- ISZFECZEQLODQT-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a][1,4]benzodiazepine-1-thione Chemical class S=C1N=NC=2N1C1=C(C=NC2)C=CC=C1 ISZFECZEQLODQT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- WULCMEBFNHGYFB-UHFFFAOYSA-N (5-phenyl-3h-1,4-benzodiazepin-2-yl)hydrazine Chemical compound N=1CC(NN)=NC2=CC=CC=C2C=1C1=CC=CC=C1 WULCMEBFNHGYFB-UHFFFAOYSA-N 0.000 description 1
- ZGBRDDCNIPCLMZ-UHFFFAOYSA-N (7-nitro-5-phenyl-3h-1,4-benzodiazepin-2-yl)hydrazine Chemical compound N=1CC(NN)=NC2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 ZGBRDDCNIPCLMZ-UHFFFAOYSA-N 0.000 description 1
- ILMRDZINEBHGMC-UHFFFAOYSA-N 1-[(7-chloro-5-phenyl-3H-1,4-benzodiazepin-2-yl)amino]-3-phenylthiourea Chemical compound ClC=1C=CC2=C(C(=NCC(=N2)NNC(=S)NC2=CC=CC=C2)C2=CC=CC=C2)C1 ILMRDZINEBHGMC-UHFFFAOYSA-N 0.000 description 1
- OUGXLBQUBTVOFM-UHFFFAOYSA-N 1-[(7-chloro-5-phenyl-3H-1,4-benzodiazepin-2-yl)amino]-3-phenylurea Chemical compound ClC=1C=CC2=C(C(=NCC(=N2)NNC(=O)NC2=CC=CC=C2)C2=CC=CC=C2)C1 OUGXLBQUBTVOFM-UHFFFAOYSA-N 0.000 description 1
- TZZMFMFEBJSMSP-UHFFFAOYSA-N 1-[[7-chloro-5-(4-methoxyphenyl)-3H-1,4-benzodiazepin-2-yl]amino]-3-methylurea Chemical compound ClC=1C=CC2=C(C(=NCC(=N2)NNC(=O)NC)C2=CC=C(C=C2)OC)C=1 TZZMFMFEBJSMSP-UHFFFAOYSA-N 0.000 description 1
- OKSINCZQDWSATA-UHFFFAOYSA-N 7-nitro-5-phenyl-3h-1,4-benzodiazepin-2-amine Chemical compound N=1CC(N)=NC2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 OKSINCZQDWSATA-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- GQZZWGZHSUQJNS-UHFFFAOYSA-N [7-chloro-5-(4-methoxyphenyl)-3h-1,4-benzodiazepin-2-yl]hydrazine Chemical compound C1=CC(OC)=CC=C1C1=NCC(NN)=NC2=CC=C(Cl)C=C12 GQZZWGZHSUQJNS-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-N anhydrous cyanic acid Natural products OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 239000012768 molten material Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/20—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Analogifremgangsmåte til fremstilling av Analogy method for the production of
terapeutisk aktive benzodiazepinderivater. therapeutically active benzodiazepine derivatives.
Foreliggende oppfinnelse angår en analogifremgangsmåte til fremstilling av nye, terapeutisk aktive 1-okso- eller 1-tiokso-s-tria-zolo [4 ,3-a] [T,il]benzodiazepinderivater med den generelle formel: The present invention relates to an analogue method for the preparation of new, therapeutically active 1-oxo- or 1-thioxo-s-triazolo [4,3-a] [T,yl]benzodiazepine derivatives with the general formula:
hvor PL er hydrogen, halogen, nitro, trifluormetyl, eller lavere alkyl, FL er hydrogen, halogen eller lavere alkoksy, X er oksygen eller svovel, og hvor nitrogenatomet i 5-stillingen kan være forbundet med et oksygenatom, samt farmasøytisk akseptable salter av ovennevnte derivater. 1-okso- eller 1-tiokso-s-triazolo[4,3-a][l,4]benzodiazepinderivater med formel (IV) fremstilles ifølge oppfinnelsen ved ring-slutning av 2-(4-substituert semikarbazido)- eller 2-(4-substituert tiosemikarbazido)-l,4-benzodiazepinderivater med formel III. Denne reaksjon samt fremstillingen av utgangsforbindelsene med formel III where PL is hydrogen, halogen, nitro, trifluoromethyl, or lower alkyl, FL is hydrogen, halogen or lower alkoxy, X is oxygen or sulfur, and where the nitrogen atom in the 5-position may be connected to an oxygen atom, as well as pharmaceutically acceptable salts of the above derivatives. 1-oxo- or 1-thioxo-s-triazolo[4,3-a][1,4]benzodiazepine derivatives of formula (IV) are prepared according to the invention by ring closure of 2-(4-substituted semicarbazido)- or 2- (4-Substituted thiosemicarbazido)-1,4-benzodiazepine derivatives of formula III. This reaction as well as the preparation of the starting compounds of formula III
hvor R^, og X har samme betydninger som angitt ovenfor, R' er en alkyl-, cykloalkyl-, aryl- eller aralkylgruppe, og hvor nitrogenatomet i 4-stillingen i formel I og III og i 5-stillingen i formel IV kan være forbundet med et oksygenatom. Når nitrogenatomet i 5-stillingen i det erholdte produkt er forbundet med et oksygenatom, kan where R^ and X have the same meanings as stated above, R' is an alkyl, cycloalkyl, aryl or aralkyl group, and where the nitrogen atom in the 4-position in formulas I and III and in the 5-position in formula IV can be connected to an oxygen atom. When the nitrogen atom in the 5-position in the product obtained is connected to an oxygen atom, can
produktet om ønsket behandles med et desoksygeneringsmiddel. Det erholdte produkt kan også om ønsket omdannes til terapeutisk akseptable salter derav. if desired, the product is treated with a deoxygenator. The product obtained can also, if desired, be converted into therapeutically acceptable salts thereof.
Trinn 1: Forbindelsen (I) omsettes med isocyansyreester eller en isotiocyansyreester med formel II. Vanligvis vil reaksjonen fordel-aktig skje i nærvær av et egnet oppløsningsmiddel, f.eks. aromatiske hydrokarboner, pyridin, tetrahydrofuran, kloroform, dimetylformamid og alkoholer (f.eks. metanol, etanol), ved romtemperatur eller under denne. Reaksjonen kan om ønsket utføres under oppvarming. Mengden av forbindelsen med formel II varierer vanligvis fra 1 til 1.5 mol i forhold til 1 mol av forbindelsen med formel I. Det resulterende 2-(4-substituerte semikarbazido)- eller 2-(4-substituerte tiosemi-karbazido)-l,4-benzodiazepinderivat (III) kan innvinnes i enhver ønsket renhet ved en i og for seg kjent metode (f.eks. destillasjon eller omkrystallisering). Step 1: The compound (I) is reacted with isocyanic acid ester or an isothiocyanic acid ester of formula II. Usually, the reaction will advantageously take place in the presence of a suitable solvent, e.g. aromatic hydrocarbons, pyridine, tetrahydrofuran, chloroform, dimethylformamide and alcohols (eg methanol, ethanol), at or below room temperature. If desired, the reaction can be carried out under heating. The amount of the compound of formula II usually varies from 1 to 1.5 mol relative to 1 mol of the compound of formula I. The resulting 2-(4-substituted semicarbazido)- or 2-(4-substituted thiosemicarbazido)-1,4 -benzodiazepine derivative (III) can be recovered in any desired purity by a method known per se (e.g. distillation or recrystallization).
Trinn 2: Forbindelsen med formel III fremstilt under trinn 1 blir så underkastet en ringslutningsreaksjon. Vanligvis skjer reaksjonen glatt ved oppvarming til ca. 120° til 250°C fulgt av en eliminering av et alkyl-, aralkyl- eller arylamin. Reaksjonen kan utføres ved å oppvarme forbindelsen III til dets smeltepunkt uten et nærvær av opp-løsningsmidler, eller ved en oppvarming i et egnet oppløsningsmiddel slik som pyridin, kollidin, dimetylformamid, xylen, tetralin eller di-fenyleter. Step 2: The compound of formula III prepared during step 1 is then subjected to a cyclization reaction. Usually, the reaction occurs smoothly when heated to approx. 120° to 250°C followed by an elimination of an alkyl, aralkyl or aryl amine. The reaction can be carried out by heating the compound III to its melting point without the presence of solvents, or by heating in a suitable solvent such as pyridine, collidine, dimethylformamide, xylene, tetralin or diphenyl ether.
Trinn 1 og trinn 2 kan utføres i rekkefølge med eller uten isolering av forbindelsen III. Således kan f.eks. reaksjonen mellom forbindelsene I og II utføres ved å oppvarme det hele i nærvær av et oppløsningsmiddel slik som pyridin, kollidin eller lignende, hvorved den ønskede forbindelse med formel IV oppnås med en gang. Step 1 and step 2 can be carried out in sequence with or without isolation of compound III. Thus, e.g. the reaction between compounds I and II is carried out by heating the whole in the presence of a solvent such as pyridine, collidine or the like, whereby the desired compound of formula IV is obtained at once.
I det tilfelle at nitrogenatomet i 5-stillingen er knyttet til et oksygenatom, så kan dette som nevnt, om ønsket, fjernes ved én reduksjon med et egnet deoksygenerende middel, f.eks. et fosfortri-halogenid (f.eks. fosfortriklorrd) eller ved katalytisk hydrogener-ingi Forbindelse IV fremstilt på ovennevnte måte kan innvinnes i In the event that the nitrogen atom in the 5-position is linked to an oxygen atom, as mentioned, this can, if desired, be removed by one reduction with a suitable deoxygenating agent, e.g. a phosphorus trihalide (e.g. phosphorus trichloride) or by catalytic hydrogenation Compound IV prepared in the above manner can be recovered in
ønsket renhet ved i og for seg kjent metode, f,.eks. ved omkrystallisering. desired purity by a method known per se, e.g. by recrystallization.
Forbindelsen.méd formel IV har basiske -nitrpgenatomer i molekylet og kan følgelig innvinnes i form av farmasøytisk akseptable syresalter (f„eks. hydroklorid, sxilfatj fosfat,, oks.alat, -malonat, succinat., tart ar at, eit rat, etc.). " The compound of formula IV has basic nitrogen atoms in the molecule and can therefore be recovered in the form of pharmaceutically acceptable acid salts (e.g. hydrochloride, xylfatj phosphate, oxalate, -malonate, succinate, tartar at, eit rat, etc .). "
Nevnte 1-okso- eller 1-tiokso-s-triazolo[4,3-a][1,4]-benzodi-azepinderivater med formel IV lean -danne tautomere med den generelle formel.: hvor ringene R^, R,, og X har samme betydning som angitt ovenfor, mens nitrogenatomet i 5-stillingen eventuelt kan være knyttet til et oksygenatom. Disse tautomere inngår også som fremstillingsprodukter i foreliggende oppfinnelse. Said 1-oxo- or 1-thioxo-s-triazolo[4,3-a][1,4]-benzodiazepine derivatives of formula IV lean -forming tautomers of the general formula.: where the rings R^, R,, and X has the same meaning as stated above, while the nitrogen atom in the 5-position may optionally be linked to an oxygen atom. These tautomers are also included as manufacturing products in the present invention.
Forbindelsene IV fremstilt ved foreliggende fremgangsmåte er nye og har bemerkelsesverdige farmakologiske virkninger >på sentral-nervesystemet, nemlig ved at de er muskelavslappende, antikrampemid-ler, sedativer og søvninduserende midler, og de kan følgelig brukes som legemidler for avslapning av muskler, mot kramper, som berolig-ende middel og som sovemiddel. Nevnte forbindelser og syresalter av disse kan anvendes oralt eller parenteralt som sådanne, eller kan om ønsket blandes med farmasøytisk akseptable bærere og opparbeides i en egnet farmasøytisk form, f.eks. som et pulver, som pellets, som tab-letter eller som injeksjonsoppløsninger. Den anvendte mengde for administrasjon vil være avhengig av forbindelsene, sykdommens type og natur, etc. , men vil vanligvis variere fra 1 til 30 mg per døgn for voksne pasienter ved oral administrasjon. The compounds IV produced by the present process are new and have remarkable pharmacological effects > on the central nervous system, namely in that they are muscle relaxants, anticonvulsants, sedatives and sleep-inducing agents, and they can consequently be used as drugs for muscle relaxation, against convulsions, as a sedative and as a sleeping aid. Said compounds and their acid salts can be used orally or parenterally as such, or can, if desired, be mixed with pharmaceutically acceptable carriers and processed into a suitable pharmaceutical form, e.g. as a powder, as pellets, as tablets or as injection solutions. The amount used for administration will depend on the compounds, the type and nature of the disease, etc., but will usually vary from 1 to 30 mg per day for adult patients by oral administration.
Følgende eksempler illustrerer oppfinnelsen. I disse eksempler betyr deler vektdeler hvis intet annet er angitt, og forholdet mellom vektdeler og volumdeler tilsvarer forholdet mellom gram og ml. The following examples illustrate the invention. In these examples, parts means parts by weight unless otherwise stated, and the ratio of parts by weight to parts by volume corresponds to the ratio of grams to ml.
Eksempel 1 Example 1
a) En oppløsning av 1H. 2 deler 7-klor-2-hydrazino-5-fenyl-3H-l,1J-benzodiazepin i 250 volumdeler tetrahydrofuran ble dråpevis a) A solution of 1H. 2 parts of 7-chloro-2-hydrazino-5-phenyl-3H-1,1J-benzodiazepine in 250 parts by volume of tetrahydrofuran were added dropwise
tilsatt 3.5 volumdeler metylisocyanat under isavkjøling og omrøring. Etter en times omrøring ble blandingen heilt over i 2000 volumdeler vann. Bunnfallet ble oppsamlet ved filtrering, vasket med vann og aceton og så tørket, hvorved man fikk fremstilt 7-klor-2-(4-metyl-semikarbazido,)-5-fenyl-3H-l,<i>J-benzodiazepin som krystaller. Omkrystallisering fra dimetylformamid-vann gir fargeløse nåler, smeltepunkt 2iJ7°C (dekomp.). added 3.5 parts by volume of methyl isocyanate under ice-cooling and stirring. After stirring for an hour, the mixture was completely poured into 2000 parts by volume of water. The precipitate was collected by filtration, washed with water and acetone and then dried, whereby 7-chloro-2-(4-methyl-semicarbazido,)-5-phenyl-3H-1,<i>J -benzodiazepine was prepared as crystals . Recrystallization from dimethylformamide-water gives colorless needles, melting point 2iJ7°C (decomp.).
Elementæranalyse: Elemental analysis:
Beregnet for C^H-^Clf^O: C 59.73; H 4.72; N 20.49 Calculated for C^H-^Clf^O: C 59.73; H 4.72; N 20.49
Funnet: C 59.53; H 4.62; N 20.80. Found: C 59.53; H 4.62; N 20.80.
b) 6.8 deler 7-klor-2-(4-mety.lsemikarbazido)-5-fenyl-3H-l,4-benzodiazepin fremstilt som angitt i eksempel 1 a) ble oppvarmet til b) 6.8 parts of 7-chloro-2-(4-methylsemicarbazido)-5-phenyl-3H-1,4-benzodiazepine prepared as indicated in example 1 a) were heated to
250°C under omrøring, hvorved utgangsmaterialet smelter under skumdannelse. Etter oppvarming i ca. 15 minutter inntil skumdannelsen stanset opp, ble det smeltede stoff behandlet med etylacetat, hvorved man oppnådde 8-klor-6-fenyl-2,4-dihydro-1H-s-triazolo[4,3-a][1,4]-benzodiazepin-l-on som krystaller. Omkrystallisering fra metanol gir fargeløse nåler, smeltepunkt 252° - 253°C. 250°C with stirring, whereby the starting material melts while foaming. After heating for approx. 15 minutes until foaming ceased, the molten material was treated with ethyl acetate, whereby 8-chloro-6-phenyl-2,4-dihydro-1H-s-triazolo[4,3-a][1,4]- benzodiazepine-l-one as crystals. Recrystallization from methanol gives colorless needles, melting point 252° - 253°C.
Elementæranalyse: Elemental analysis:
Beregnet for C-^H^CIN^O: C 61.84; H 3.57; N 18.03 Calculated for C-^H^CIN^O: C 61.84; H 3.57; N 18.03
Funnet: C 61.83; H 3.47; N 18.18. Found: C 61.83; H 3.47; N 18.18.
Eksempel 2 Example 2
En blanding av 5.1 deler 7-klor-2-(4-metylsemikarbazido)-5-fenyl-3H-l,4-benzodiazepin fremstilt som angitt i eksempel 1 a) og l80 volumdeler pyridin ble kokt under tilbakeløp i 35 timer inntil utviklingen av metylamin ikke kunne observeres. Oppløsningsmidlet ble fradestillert under redusert trykk, og residuet behandlet med etylacetat, hvorved man fikk fremstilt 8-klor-6-fenyl-2,4-dihydro-lH-s-triazolo[4,3-a][l,4]benzodiazepin-l-on som krystaller. Omkrystallisering fra metanol gir fargeløse nåler, som smelter ved 252° 253°C A mixture of 5.1 parts of 7-chloro-2-(4-methylsemicarbazido)-5-phenyl-3H-1,4-benzodiazepine prepared as indicated in Example 1 a) and 180 parts by volume of pyridine was refluxed for 35 hours until the development of methylamine could not be observed. The solvent was distilled off under reduced pressure, and the residue treated with ethyl acetate, whereby 8-chloro-6-phenyl-2,4-dihydro-1H-s-triazolo[4,3-a][1,4]benzodiazepine- l-on as crystals. Recrystallization from methanol gives colorless needles, melting at 252°-253°C
Dette produkt er identisk med forbindelsen oppnådd i eksempel lb). This product is identical to the compound obtained in example lb).
Eksempel 3 Example 3
En oppløsning av 2.8.5 deler 7-klor-2-hydrazino-5-fenyl-3H-1,4-benzodiazepin i 120 volumdeler pyridin ble tilsatt 0.7 volumdeler metylisocyanat under isavkjø.ling og omrøring, hvoretter blandingen ble holdt på romtemperatur i 30 minutter. Etter koking under tilbakeløp i 35 timer ble oppløsningsmidlet fradestillert under redusert trykk. Residuet ble behandlet med etylacetat, hvorved man fikk oppnådd 8-klor-6-f enyl-2,4-dihydro-lH-s-triazolo.[ 4,3-a] [ 1,4 ]-benzodiazepin-l-on som krystaller.. Omkrystallisering fra metanol gir fargeløse nåler, .smeltepunkt 252° - 253°C. A solution of 2.8.5 parts of 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in 120 parts by volume of pyridine was added 0.7 parts by volume of methyl isocyanate under ice-cooling and stirring, after which the mixture was kept at room temperature for 30 minutes. After refluxing for 35 hours, the solvent was distilled off under reduced pressure. The residue was treated with ethyl acetate, whereby 8-chloro-6-phenyl-2,4-dihydro-1H-s-triazolo.[4,3-a][1,4]-benzodiazepine-1-one was obtained as crystals.. Recrystallization from methanol gives colorless needles, m.p. 252° - 253°C.
Dette produkt er identisk med forbindelsen fremstilt som angitt i eksemplene lb) og 2. This product is identical to the compound prepared as indicated in examples 1b) and 2.
Eksempel 4 Example 4
a) En oppløsning av 1.4 deler 7-klor-2-hydrazino-5-fenyl-3H-l,4-benzodiazepin i 25 volumdeler tetrahydrofuran ble tilsatt 0.65 a) A solution of 1.4 parts of 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in 25 parts by volume of tetrahydrofuran was added 0.65
volumdeler fenylisocyanat under isavkjøling og omrøring. Etter 1 times omrøring ble den dobbelte vannmengde tilsatt blandingen. De resulterende krystaller ble oppsamlet ved filtrering, vasket med vann og aceton og tørket, hvorved man fikk fremstilt 7-klor-5-fenyl-2-(4-fenylsemikarbazido)-3H-l,4-benzodiazepin som krystaller. Omkrystallisering fra dimetylformamid-vann gir fargeløse fine nåler, smeltepunkt 220° - 221°C (dekomp.). parts by volume phenyl isocyanate under ice-cooling and stirring. After stirring for 1 hour, twice the amount of water was added to the mixture. The resulting crystals were collected by filtration, washed with water and acetone and dried, whereby 7-chloro-5-phenyl-2-(4-phenylsemicarbazido)-3H-1,4-benzodiazepine was prepared as crystals. Recrystallization from dimethylformamide-water gives colorless fine needles, melting point 220° - 221°C (decomp.).
Elementæranalyse: Elemental analysis:
Beregnet for C^H^<C>l^O: C 65.42; H 4.49; N 17.34 Funnet:' C 65.6l; H 4.30; N 17.28. Calculated for C^H^<C>1^O: C 65.42; H 4.49; N 17.34 Found:' C 65.6l; H 4.30; N 17.28.
b) En oppløsning av 4 deler 7-klor-5-fenyl-2-(4-fenylsemi-karbazido)-3H-l,4-benzodiazepin fremstilt som angitt i eksempel 4 a) i b) A solution of 4 parts of 7-chloro-5-phenyl-2-(4-phenylsemi-carbazido)-3H-1,4-benzodiazepine prepared as indicated in example 4 a) in
120 volumdeler pyridin ble kokt under tilbakeløp i 5 timer. Oppløs-ningsmidlet ble fradestillert under redusert trykk. Residuet ble behandlet med etylacetat, hvorved man fikk fremstilt 8-klor-6-fenyl-2,4-dihydro-lH-s-triazolo [4,3-a][1,4]benzodiazepin-1-on som krystaller. Omkrystallisering fra metanol gir fargeløse nåler, smeltepunkt 252° - 253°C. 120 parts by volume of pyridine were refluxed for 5 hours. The solvent was distilled off under reduced pressure. The residue was treated with ethyl acetate, whereby 8-chloro-6-phenyl-2,4-dihydro-1H-s-triazolo [4,3-a][1,4]benzodiazepine-1-one was produced as crystals. Recrystallization from methanol gives colorless needles, melting point 252° - 253°C.
Produktet er identisk med forbindelsen fremstilt som angitt i eksemplene lb), 2 og 3. The product is identical to the compound prepared as indicated in examples 1b), 2 and 3.
Eksempe1 5 Example 1 5
a) En oppløsning av 3.1 deler 7-klor-2-hydrazino-5-(p-met-oksyfenyl)-3H-l,4-benzodiazepin i 40 volumdeler pyridin ble dråpevis a) A solution of 3.1 parts of 7-chloro-2-hydrazino-5-(p-meth-oxyphenyl)-3H-1,4-benzodiazepine in 40 parts by volume of pyridine was added dropwise
tilsatt 0.7 volumdeler metylisocyanat under isavkjøling og omrøring. Etter ca. 30 minutters omrøring ble 100 volumdeler vann tilsatt blandingen. De resulterende krystaller ble oppsamlet ved filtrering, vasket med metanol og tørket, hvorved man fikk fremstilt 7-klor-5-(p-metoksyfenyl)-2-(4-metylsemikarbazido)-3H-l,4-benzodiazepin som krystaller. Omkrystallisering fra dimetylformamid-vann gir fargeløse, fine nåler, smeltepunkt 234° - 235°C (dekomp.). added 0.7 parts by volume of methyl isocyanate under ice-cooling and stirring. After approx. After 30 minutes of stirring, 100 parts by volume of water were added to the mixture. The resulting crystals were collected by filtration, washed with methanol and dried, whereby 7-chloro-5-(p-methoxyphenyl)-2-(4-methylsemicarbazido)-3H-1,4-benzodiazepine was prepared as crystals. Recrystallization from dimethylformamide-water gives colourless, fine needles, melting point 234° - 235°C (decomp.).
Elementæranalyse: Elemental analysis:
Beregnet for C^gH^ClN^: C 58.14; H 4.88; N 18.84 Funnet: C 57.83; H 4.74; N 19.17. Calculated for C^gH^ClN^: C 58.14; H 4.88; N 18.84 Found: C 57.83; H 4.74; N 19.17.
b) En oppløsning av 2.0 deler 7-klor-5- (p--metr'--*;f snyl )-2-(4-metylsemikarbazido)-3H-l,4-benzodiazepin, fremstilt som angitt i eksempel 5 a), i 70 volumdeler pyridin ble kokt under tilbakeløp i 36 timer. Oppløsningsmidlet ble fradestillert under redusert trykk. Residuet ble behandlet med etylacetat, hvorved man fikk fremstilt 8-klor-6- (p-metoksyfenyl")-2 ,4-dihydro- 1H-s-triazolo[4 ,3-a] [1,4 ]-benzo-'diazepin-l-on som krystaller. Omkrystallisering fra metanol gir farge-løse nåler, smeltepunkt 257° - 258°C. ;Elementæranalyse: ;Beregnet for C^H^CIN^: C 59.92; H 3.82; N l6."44 ;Funnet: C 60.16; H 3.77; N 16.-22. Eksempel 6 a) En blanding av 2.8 volumdeler 2-amino-7-nitro-5-fenyl-3H-1,4-benzodiazepin og-2 volumdeler hydrazinhydrat ble omrørt ved romtemperatur i 1 time og så heilt over i isvann. Kloroformlaget ble vasket med vann og tørket over vannfritt natriumsulfat. Oppløsnings-midlet ble fradestillert., hvorved man fikk fremstilt 2-hydrazino-7-nitro-5-fenyl-3H-l,4-bénzodiazepin som et viskøst, oljeaktig stoff. ;Det således fremstilte 2-hydrazinoderivat ble oppløst i ;20 volumdeler pyridin og så tilsatt 1.1 volumdeler metylisocyanat ved isavkjøling og omrøring. Etter 1 times omrøring blir blandingen tilsatt 80 volumdeler vann. Det frembragte bunnfall ble oppsamlet ved -filtrering, vasket med aceton og tørket, hvorved man fikk fremstilt 2-(4-metylsemikarbazido)-7-nitro-5-fenyl-3H-1,4-benzodiazepiri som krystaller. Omkrystallisering fra dimetylformamid-vann gir gule, ;fine plater-, smeltepunkt 239° - 240°C (dekomp.). Elementæranalyse: ;Beregnet for C^<H>^<N>gO^: -C .57.95; H 4.5S; N 23.85 ;Funnet: C 57.98; H 4.-47; N 24.14. ;b) En oppløsning av 4.2 deler 2-("4-métylsemikarbazido)-7-nitro-5-fenyl-3H-lJ4-benzodiazepin fremstilt som angitt i eksempel 6 a) ;i 150 volumdeler pyridin ble kokt under tilbakeløp i 25 timer, hvorpå oppløsningsmidlet hie fradestillert. Residuet "ble "blandet med vann. ;-Det resulterende trunnfall. ble oppsamlet ved filtrering og tørket, "hvorved man fikk fremstilt 8-nitro-6-fenyl-2-,4-dihydro-lH-s-tria-zolo~[4 ,3-al [l,:4-]benzbdiazepin-l-on som "krystaller. Omkrystallisering fra vandig aceton gir gule nåler, smeltepunkt 199°— 20O°G. Elementæranalyse: Beregnet for C^H^t^Oy C 59.81; H 3.45; N 2.1.80 Funnet: ' C 60.00; H 3.44; N 21.77. ;Eksempel 7 ;a) En oppløsning av 3 deler 7-klor-2-hydrazino-5-fenyl-3H-1,4-benzodiazepin-4N-oksyd i 60 volumdeler pyridin ble tilsatt 0.7 ;volumdeler metylisocyanat under isavkjøling og omrøring. Etter ca. 30 minutter ble krystallene oppsamlet ved filtrering, vasket med metanol og tørket, hvorved man fikk fremstilt 7-klor-2-(4-metylsemikarba-zido)-6-fenyl-3H-l,4-benzodiazepin-4N-oksyd som krystaller. Omkrystallisering fra dimetylformamid-vann gir fargeløse, fine nåler, smeltepunkt 251° - 252°C (dekomponering). ;Elementæranalyse: ;Beregnet for C-^H-^CIN^: C 57.06; H 4.51; N 19.58 ;Funnet: C 56.86; H 4.35; N 19.81. ;b) En blanding av 3 deler 7-klor-2-(4-metylsemikarbazido)-6-fenyl-3H-l,4-benzodiazepin-4N-oksyd, fremstilt som angitt i eksempel 7 a), 60 volumdeler pyridin og 140 volumdeler dimetylformamid ble kokt under tilbakeløp i 8.5 timer, hvorpå oppløsningsmidlet ble fradestillert under redusert trykk. Residuet ble behandlet med vandig etanol, hvorved man fikk fremstilt 8-klor-6-feny1-2,4-dihydro-lH-s-triazolo[4,3-a][l,4]benzodiazepin-l-on-5N-oksyd som krystaller. Omkrystallisering fra metanol gir gule prismer av monometanolatet, smeltepunkt 164° - l66°C (skumdannelse). ;Elementæranalyse: ;Beregnet for c16H11clNlj02 .CH^OH: . C 56.91; H 4.21; N 15.62 Funnet: C 56.77; H 4.02; N 15.88. ;En omkrystallisering fra vandig etanol gir gule prismer av monohydratet, smeltepunkt 173° - 174°C (mykning). Elementæranalyse: Beregnet for c16H11clNi402-^ 2°'' C 55.74; H 3.80; N 16.25 ;Funnet: C. 55.89; H 3.85; N 16.25. ;Eksempel 8 ;En oppløsning av 2.85 deler 7-klor-2-hydrazino-5-fenyl-3H-1,4-benzodiazepin i 25 volumdeler pyridin ble tilsatt 1.5 deler fenylisotiocyanat, og blandingen ble kokt under tilbakeløp. Etter 3.5 timer ble pyridin fradestillert under redusert trykk. Residuet ble behandlet med eter, hvorved man fikk fremstilt 8-klor-6-fenyl-2,4-dihydro-lH-s-triazolo[4,3-a][l,4]benzodiazepin-l-tion som krystaller. Omkrystallisering fra metanol gir fargeløse prismer, smeltepunkt 237° - 238°C. ;Elementæranalyse: ;Beregnet for C gH^ClN^S: C 58. 79; H 3.39; N 17.14 ;Funnet: C 58.94; H 3.29; N 17.24. Eksempel 9 ;a) En oppløsning av 2.85 deler 7-klor-2-hydrazino-5-fenyl-3H-l,4-benzodiazepin i 250 volumdeler etanol ble tilsatt 1.5 deler ;fenylisotiocyanat, og blandingen hensatt ved romtemperatur i ca. 3 timer. De utfelte krystaller ble oppsamlet ved filtrering, hvorved man fikk fremstilt 7-klor-5-fenyl-2-(4-fenyltiosemikarbazido)-3H-l,4-benzodiazepin som krystaller, Omkrystallisering fra aceton gir blek-gule nåler som smelter ved 199° - 205°C (dekomp.). ;Elementæranalyse: ;Beregnet for C22Hl8ClN5S: C 62.96; H 4.31; N 16.67 ;Funnet: C 62.51; H 4.31; N 16.65. b) En oppløsning av 3 deler 7-klor-5-fenyl-2-(4-fenyltiosemi-karbazido)-3H-l,4-benzodiazepin, fremstilt som angitt i eksempel 9 a), ;i 25 volumdeler pyridin ble kokt under tilbakeløp i 2 timer, hvorpå pyridinen ble fjernet ved destillasjon under redusert trykk. Residuet ble behandlet med eter. De resulterende krystaller ble oppsamlet ved filtrering og tørket, hvorved man fikk fremstilt 8-klor-6-fenyl-2,4-dihydro-lH-s-triazolo[4,3-a][1,4]benzodiazepin-l-tion som krystaller. Omkrystallisering fra metanol gir fargeløse prismer, smeltepunkt 237° - 238°C. ;Produktet er identisk med produktet fremstilt som angitt ;i eksempel 8.. ;Eksempel 10 ;En oppløsning av 3 deler 7-klor-2-hydrazino-5-fenyl-3H-l,4-benzodiazepin-4N-oksyd i 20 volumdeler pyridin ble tilsatt 1.5 deler fenylisotiocyanat, og blandingen ble kokt under tilbakeløp i 2.5 timer. Etter avkjøling ble uløselige stoffer fjernet ved filtrering. Filtratet ble konsentrert til tørrhet under redusert trykk. Omkrystallisering av residuet fra en blanding av etanol og aceton gir 8-klor-6-fenyl-2,4-dihydro-lH-s-triazolo[4 , >a] [l,4]-benzodiazepin-l-tion-5N-oksyd som gule prismer, smeltepunkt 243° - 244°C (dekomp.). Elementæranalyse: Beregnet for C^gH^ClN^OS. 1/4 C2H5OH: C 55.93; H 3.56; N 15.81 Funnet: C 56.09; H 3.74; N 15.79. ;Eksempel 11 ;En oppløsning av 1.8 deler 8-klor-6-feny1-2,4-dihydro-1H-s-triazolo[4.3-a] [l,4]benzodiazepin-l-on-5N-oksyd (metanolat) fremstilt som angitt i eksempel 7b), i 200 volumdeler kloroform ble tilsatt 2.1 volumdeler fosfortriklorid, og blandingen kokt under tilbake-løp i 5 timer. Etter avkjøling ble de utfelte krystaller oppsamlet ved filtrering. En behandling av krystallene med fortynnet vandig ammoniakk gir 8-klor-6-fenyl-2,4-dihydro-lH-s-triazolol4,3-a][1,4]-benzodiazepin-l-on i fri form. Omkrystallisering fra metanol gir fargeløse nåler., smeltepunkt 252° - 253°C. ;Produktet er identisk med forbindelsen .fremstilt som an-.gitt i eksemplene 1 b), 2, 3 og 4 b). ;Eksempel 12 ;En blanding av 1.77 deler 7-klor-6-fenyl-2J4-dihydro-lH-s-triazolo ['4 ,3-a] [1,4 ]benzodiazepin-l-tion-5N-oksyd (1./4 etanolat), fremstilt som angitt i eksempel 10, 2.1 volumdeler fosfortriklorid og 200 volumdeler kloroform ble "kokt under tilbakeløp i ^ timer, hvorpå blandingen ble konsentrert. Residuet ble nøytralisert med fortynnet, vandig ammoniakk og ekstrahert med kloroform. Kloroformlaget ble vasket med vann, tørket over vannfri natriumsulfat og konsentrert. Residuet ble behandlet med etyleter, hvorved man fikk fremstilt 8-klor-6-fenyl-2,4-dihydro-lH-s-triazolo[4,3-a][1,4]benzodiazepin-l~ tion som krystaller. Omkrystallisering fra metanol gir fargeløse nåler, smeltepunkt 23^4° - 236°"C. ;Produktet er identisk med produktet fra eksemplene 8 og ;9 b). ;Følgende forbindelser ble fremstilt under anvendelse av ;.metoder i likhet med de ovenfor angitte. ;Eksempel. 1. 3 ;Omsetning av 7-klor-"5-(2-klorfenyl)-2-hydrazin-o-.3H-l,4-benzodiazepin med metylisocyanat ga 7—klor-5- (2-klorfenyl)-2- (^4-metyl-semikarbazido^-3H-JL,4-benzodiazepin (gule prismer fra vandig dimetylformamid), smeltepunkt 230° - 232°C (dekomp.), som ble kokt under til-bakeløp i pyridin-dimetylformamid hvilket ga 8~klor-6-(2-klorfenyl)-2 ,4-dihydro-lH-s-triazolo£4.,3-a]Il,4]benzodiazepin-l-on, i form av fargeløse nåler fra kloroform-metanol, smeltepunkt 205° - 208°C. Elementæranalyse: Beregnet for C^gH^ClgltyO: C 55.67"; H 2.92; "N 16.23 Purme-t:. C 55-77; « 2.76.-; H 1-6.30*b) A solution of 2.0 parts of 7-chloro-5-(p--metr'--*;f-synyl)-2-(4-methylsemicarbazido)-3H-1,4-benzodiazepine, prepared as indicated in example 5 a ), in 70 parts by volume of pyridine was refluxed for 36 hours. The solvent was distilled off under reduced pressure. The residue was treated with ethyl acetate, whereby 8-chloro-6-(p-methoxyphenyl")-2,4-dihydro-1H-s-triazolo[4,3-a][1,4]-benzo-' diazepin-l-one as crystals. Recrystallization from methanol gives colorless needles, melting point 257° - 258° C. ;Elementary analysis: ;Calculated for C^H^CIN^: C 59.92; H 3.82; N l6."44 ; Found: C 60.16; H 3.77; N 16.-22. Example 6 a) A mixture of 2.8 parts by volume of 2-amino-7-nitro-5-phenyl-3H-1,4-benzodiazepine and 2 parts by volume of hydrazine hydrate was stirred at room temperature for 1 hour and then completely poured into ice water. The chloroform layer was washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off, whereby 2-hydrazino-7-nitro-5-phenyl-3H-1,4-benzodiazepine was produced as a viscous, oily substance. The 2-hydrazino derivative thus prepared was dissolved in 20 parts by volume of pyridine and then 1.1 parts by volume of methyl isocyanate was added with ice-cooling and stirring. After 1 hour of stirring, 80 parts by volume of water are added to the mixture. The resulting precipitate was collected by filtration, washed with acetone and dried, whereby 2-(4-methylsemicarbazido)-7-nitro-5-phenyl-3H-1,4-benzodiazepyri was produced as crystals. Recrystallization from dimethylformamide-water gives yellow, fine plates, melting point 239° - 240°C (decomp.). Elemental analysis: ;Calculated for C^<H>^<N>gO^: -C .57.95; H 4.5S; N 23.85 ;Found: C 57.98; H 4.-47; N 24.14. b) A solution of 4.2 parts of 2-((4-methylsemicarbazido)-7-nitro-5-phenyl-3H-1J4-benzodiazepine prepared as indicated in example 6 a) in 150 parts by volume of pyridine was refluxed for 25 hours , whereupon the solvent was distilled off. The residue was mixed with water. The resulting precipitate was collected by filtration and dried to give 8-nitro-6-phenyl-2-,4-dihydro-lH-s -tria-zolo~[4 ,3-al [l,:4-]benzbdiazepin-l-one as "crystals. Recrystallization from aqueous acetone gives yellow needles, mp 199°— 200°G. Elemental analysis: Calculated for C^H ^t^Oy C 59.81; H 3.45; N 2.1.80 Found: ' C 60.00; H 3.44; N 21.77. ;Example 7 ;a) A solution of 3 parts of 7-chloro-2-hydrazino-5-phenyl-3H -1,4-benzodiazepine-4N-oxide in 60 parts by volume of pyridine was added to 0.7 parts by volume of methyl isocyanate under ice-cooling and stirring. After about 30 minutes, the crystals were collected by filtration, washed with methanol and dried, whereby 7-chloro- 2-(4-methylsemicarbazido)-6-phen yl-3H-1,4-benzodiazepine-4N-oxide as crystals. Recrystallization from dimethylformamide-water gives colourless, fine needles, melting point 251° - 252°C (decomposition). ;Elementary analysis: ;Calculated for C-^H-^CIN^: C 57.06; H 4.51; N 19.58 ;Found: C 56.86; H 4.35; N 19.81. ;b) A mixture of 3 parts of 7-chloro-2-(4-methylsemicarbazido)-6-phenyl-3H-1,4-benzodiazepine-4N-oxide, prepared as indicated in example 7 a), 60 parts by volume of pyridine and 140 parts by volume of dimethylformamide was refluxed for 8.5 hours, after which the solvent was distilled off under reduced pressure. The residue was treated with aqueous ethanol, whereby 8-chloro-6-phenyl-2,4-dihydro-1H-s-triazolo[4,3-a][1,4]benzodiazepine-1-one-5N- oxide as crystals. Recrystallization from methanol gives yellow prisms of the monomethanolate, melting point 164° - 166°C (foaming). ;Elementary analysis: ;Calculated for c16H11clNlj02 .CH^OH: . C 56.91; H 4.21; N 15.62 Found: C 56.77; H 4.02; N 15.88. ;A recrystallization from aqueous ethanol gives yellow prisms of the monohydrate, melting point 173° - 174°C (softening). Elemental analysis: Calculated for c16H11clNi402-^ 2°'' C 55.74; H 3.80; N 16.25 ;Found: C. 55.89; H 3.85; Thu 16.25. ;Example 8 ;A solution of 2.85 parts of 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in 25 parts by volume of pyridine was added with 1.5 parts of phenylisothiocyanate, and the mixture was boiled under reflux. After 3.5 hours, pyridine was distilled off under reduced pressure. The residue was treated with ether, whereby 8-chloro-6-phenyl-2,4-dihydro-1H-s-triazolo[4,3-a][1,4]benzodiazepine-1-thione was produced as crystals. Recrystallization from methanol gives colorless prisms, melting point 237° - 238°C. ;Elementary analysis: ;Calculated for C gH^ClN^S: C 58. 79; H 3.39; N 17.14 ;Found: C 58.94; H 3.29; N 17.24. Example 9 ;a) A solution of 2.85 parts of 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in 250 parts by volume of ethanol was added with 1.5 parts of phenylisothiocyanate, and the mixture was left at room temperature for approx. 3 hours. The precipitated crystals were collected by filtration, whereby 7-chloro-5-phenyl-2-(4-phenylthiosemicarbazido)-3H-1,4-benzodiazepine was produced as crystals. Recrystallization from acetone gives pale yellow needles melting at 199 ° - 205°C (decomp.). ;Elementary analysis: ;Calculated for C22Hl8ClN5S: C 62.96; H 4.31; N 16.67 ;Found: C 62.51; H 4.31; N 16.65. b) A solution of 3 parts of 7-chloro-5-phenyl-2-(4-phenylthiosemi-carbazido)-3H-1,4-benzodiazepine, prepared as indicated in example 9 a), in 25 parts by volume of pyridine was boiled under refluxed for 2 hours, after which the pyridine was removed by distillation under reduced pressure. The residue was treated with ether. The resulting crystals were collected by filtration and dried to give 8-chloro-6-phenyl-2,4-dihydro-1H-s-triazolo[4,3-a][1,4]benzodiazepine-1-thione as crystals. Recrystallization from methanol gives colorless prisms, melting point 237° - 238°C. ;The product is identical to the product prepared as indicated ;in example 8.. ;Example 10 ;A solution of 3 parts 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine-4N-oxide in 20 parts by volume pyridine was added to 1.5 parts of phenyl isothiocyanate, and the mixture was refluxed for 2.5 hours. After cooling, insoluble substances were removed by filtration. The filtrate was concentrated to dryness under reduced pressure. Recrystallization of the residue from a mixture of ethanol and acetone gives 8-chloro-6-phenyl-2,4-dihydro-lH-s-triazolo[4 , >a] [l,4]benzodiazepine-l-thione-5N- oxide as yellow prisms, melting point 243° - 244°C (decomp.). Elemental analysis: Calculated for C^gH^ClN^OS. 1/4 C 2 H 5 OH: C 55.93; H 3.56; N 15.81 Found: C 56.09; H 3.74; N 15.79. ;Example 11 ;A solution of 1.8 parts of 8-chloro-6-phenyl-2,4-dihydro-1H-s-triazolo[4.3-a] [1,4]benzodiazepine-l-one-5N-oxide (methanolate) prepared as indicated in example 7b), in 200 parts by volume of chloroform, 2.1 parts by volume of phosphorus trichloride were added, and the mixture was boiled under reflux for 5 hours. After cooling, the precipitated crystals were collected by filtration. A treatment of the crystals with dilute aqueous ammonia gives 8-chloro-6-phenyl-2,4-dihydro-1H-s-triazolol4,3-a][1,4]-benzodiazepine-1-one in free form. Recrystallization from methanol gives colorless needles., melting point 252° - 253°C. The product is identical to the compound prepared as indicated in examples 1 b), 2, 3 and 4 b). ;Example 12 ;A mixture of 1.77 parts of 7-chloro-6-phenyl-2J4-dihydro-lH-s-triazolo ['4 ,3-a] [1,4 ]benzodiazepine-l-thione-5N-oxide (1 ./4 ethanolate), prepared as indicated in Example 10, 2.1 parts by volume of phosphorus trichloride and 200 parts by volume of chloroform were "refluxed for ^ hours, after which the mixture was concentrated. The residue was neutralized with dilute aqueous ammonia and extracted with chloroform. The chloroform layer was washed with water, dried over anhydrous sodium sulfate and concentrated.The residue was treated with ethyl ether to give 8-chloro-6-phenyl-2,4-dihydro-1H-s-triazolo[4,3-a][1,4 ]benzodiazepine-l~ tion as crystals. Recrystallization from methanol gives colorless needles, mp 23^4° - 236°"C. The product is identical to the product from examples 8 and 9 b). The following compounds were prepared using methods similar to those set forth above. ;Example. 1. 3 ;Reaction of 7-chloro-"5-(2-chlorophenyl)-2-hydrazine-o-.3H-1,4-benzodiazepine with methyl isocyanate gave 7-chloro-5-(2-chlorophenyl)-2- (^4-methyl-semicarbazido^-3H-JL,4-benzodiazepine (yellow prisms from aqueous dimethylformamide), mp 230° - 232°C (decomp.), which was refluxed in pyridine-dimethylformamide to give 8 ~chloro-6-(2-chlorophenyl)-2,4-dihydro-1H-s-triazolo£4,3-a]Il,4]benzodiazepine-1-one, in the form of colorless needles from chloroform-methanol, melting point 205° - 208° C. Elemental analysis: Calculated for C^gH^ClgltyO: C 55.67"; H 2.92; "N 16.23 Purme-t:. C 55-77; « 2.76.-; H 1-6.30*
Eksempel 14 Example 14
Omsetning av 2-hydrazino-5-fenyl-3H-l,4-benzodiazepin med metylisocyanat ga 2-(4-metylsemikarbazido)-5-fenyl-3H-l,4-benzodiaze-pin (fargeløse, pulverformige krystaller, smeltepunkt 233° - 234°C), som ble kokt under tilbakeløp i pyridin-dimetylformamid hvilket ga Reaction of 2-hydrazino-5-phenyl-3H-1,4-benzodiazepine with methyl isocyanate gave 2-(4-methylsemicarbazido)-5-phenyl-3H-1,4-benzodiazepine (colorless, powdery crystals, m.p. 233° - 234°C), which was refluxed in pyridine-dimethylformamide which gave
6-fenyl-2,4-dihydro-lH-s-triazolo[4,3-a][l,4]benzodiazepin-l-on, i form av fargeløse nåler fra metanol, smeltepunkt 236° - 237°C. Elementæranalyse: 6-phenyl-2,4-dihydro-lH-s-triazolo[4,3-a][l,4]benzodiazepine-l-one, in the form of colorless needles from methanol, melting point 236° - 237°C. Elemental analysis:
Beregnet for C^H-^N^O: C 69.55; H- 4.37; N 20.28 Calculated for C^H-^N^O: C 69.55; H- 4.37; N 20.28
Funnet: C 69.39; H 4.27; N 20.12. Found: C 69.39; H 4.27; N 20.12.
Eksempel 15 Example 15
Omsetning av 2-hydrazino-7-metyl-5-fenyl-'3H-l,4-benzo-diazepin med metylisocyanat ga 7-metyl-2-(4-metylsemikarbazido)-5-fenyl-3H-l,4-benzodiazepin (lysegule prismer fra vandig dimetylformamid ) , smeltepunkt 229° - 231°C, som ble tilbakeløpskokt i pyridin-dimetylf ormamid og dette resulterte i oppnåelsen av 8-metyl-6-fenyl-2,4-dihydro-lH-s-triazolo[4,3-a]t1,4]benzodiazepin-l-on i form av fargeløse prismer (fra metanol), smeltepunkt 242° - 244°C. Elementæranalyse: Reaction of 2-hydrazino-7-methyl-5-phenyl-'3H-1,4-benzodiazepine with methyl isocyanate gave 7-methyl-2-(4-methylsemicarbazido)-5-phenyl-3H-1,4-benzodiazepine (light yellow prisms from aqueous dimethylformamide ), melting point 229° - 231°C, which was refluxed in pyridine-dimethylformamide and this resulted in obtaining 8-methyl-6-phenyl-2,4-dihydro-lH-s-triazolo[ 4,3-a]t1,4]benzodiazepine-l-one in the form of colorless prisms (from methanol), melting point 242° - 244°C. Elemental analysis:
Beregnet for C^H^<N>^<O:> C 70.33; H 4.86; N 19.30 Calculated for C^H^<N>^<O:> C 70.33; H 4.86; Thu 19.30
Funnet: C 70.18; H 4.81; N 19.36. Found: C 70.18; H 4.81; N 19.36.
Eksempel 16 Example 16
Omsetning av 7-klor-5-(^-klorfenyl)-2-hydrazino-3H-l,4-benzodiazepin-4N-oksyd med metylisocyanat ga 7~klor-5-(4-klorfenyl)-2-(4-metylsemikarbazido)-3H-l,4-benzodiazepin-4N-oksyd (fargeløse pulverformige krystaller, smeltepunkt 256° - 257°C), som ble tilbake-løpskokt i pyridin-dimetylformamid hvilket ga 8-klor-6-(4-klorfenyl)-2,4-dihydro-1H-s-triazolo[4,3-a][l,4]benzodiazepin-l-on-5N-oksyd, fargeløse krystaller (fra metanol), smeltepunkt 188° - 190°C. Elementæranalyse: Beregnet for C16H10C12NH°2: C 53.20; H 2.79; N 15.51 Funnet: C 52.92; H 2.62; N 14.89. Reaction of 7-chloro-5-(^-chlorophenyl)-2-hydrazino-3H-1,4-benzodiazepine-4N-oxide with methyl isocyanate gave 7-chloro-5-(4-chlorophenyl)-2-(4-methylsemicarbazido )-3H-1,4-benzodiazepine-4N-oxide (colorless powdery crystals, mp 256°-257°C), which was refluxed in pyridine-dimethylformamide to give 8-chloro-6-(4-chlorophenyl)- 2,4-dihydro-1H-s-triazolo[4,3-a][1,4]benzodiazepine-1-one-5N-oxide, colorless crystals (from methanol), melting point 188° - 190°C. Elemental analysis: Calculated for C16H10C12NH°2: C 53.20; H 2.79; N 15.51 Found: C 52.92; H 2.62; N 14.89.
Eksempel 17 Example 17
Omsetning av 2-hydrazino-7-nitro-5~fenyl-3H-l,4-benzo-diazepin-4N-oksyd med metylisocyanat ga 2-(4-metylsemikarbazido)-7-nitro-5-fenyl-3H-l,4-benzodiazepin-4N-oksyd (gule nåler fra vandig dimetylformamid, smeltepunkt 243° - 244°C (dekomp.)), som ble til-bakeløpskokt i pyridin og dette ga 8-nitro-6-fenyl-2,4-dihydro-lH-s-triazolo[4, 3-a] [1,4]benzodiazepin- 1-on-5N-oksyd, gule prismer (fra etylacetat), smeltepunkt 234° - 237°C. Reaction of 2-hydrazino-7-nitro-5~phenyl-3H-1,4-benzo-diazepine-4N-oxide with methyl isocyanate gave 2-(4-methylsemicarbazido)-7-nitro-5-phenyl-3H-1, 4-benzodiazepine-4N-oxide (yellow needles from aqueous dimethylformamide, mp 243° - 244°C (decomp.)), which was refluxed in pyridine to give 8-nitro-6-phenyl-2,4-dihydro -1H-s-triazolo[4, 3-a] [1,4]benzodiazepine-1-one-5N-oxide, yellow prisms (from ethyl acetate), mp 234° - 237°C.
Elementæranalyse: Elemental analysis:
Beregnet for C^H^N^: C 56.97; H 3.29; N 20.77 Calculated for C^H^N^: C 56.97; H 3.29; N 20.77
Funnet: C 57.00; H 3.20; N 20.83. Found: C 57.00; H 3.20; N 20.83.
Eksempel 18 Example 18
Omsetning av 2-hydrazino-5-fenyl-7-trifluormetyl-3H-1,4-benzodiazepin-4N-oksyd med metylisocyanat ga 2-(4-metylsemikarbazido)-5-fenyl-7-trifluormetyl-3H-1,4-benzodiazepin-4N-oksyd (fargeløse pul- Reaction of 2-hydrazino-5-phenyl-7-trifluoromethyl-3H-1,4-benzodiazepine-4N-oxide with methyl isocyanate gave 2-(4-methylsemicarbazido)-5-phenyl-7-trifluoromethyl-3H-1,4- benzodiazepine-4N-oxide (colorless pul-
verformige krystaller fra vandig dimetylformamid, smeltepunkt 240° - vermiform crystals from aqueous dimethylformamide, melting point 240° -
242°C (dekomp.)), som ble tilbakeløpskokt i pyridin og dette ga 6-fenyl-8-trifluormetyl-2,4-dihydro-1H-s-triazolo[4,3-a][l,4]benzodia-zepin-l-on-5N-oksyd, fargeløse prismer (fra aceton-n-heksan), smelte- 242°C (decomp.)), which was refluxed in pyridine and this gave 6-phenyl-8-trifluoromethyl-2,4-dihydro-1H-s-triazolo[4,3-a][1,4]benzodia- zepin-l-one-5N-oxide, colorless prisms (from acetone-n-hexane), melt-
punkt 171° - 173°C point 171° - 173°C
Elementæranalyse: Elemental analysis:
Beregnet for c17^ 11F^ i^ 02: C 56.67; H 3.08; N 15.55 Calculated for c17^ 11F^ i^ 02: C 56.67; H 3.08; N 15.55
Funnet: C 56.74; H 3.27; N 15.65. Found: C 56.74; H 3.27; N 15.65.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP44092366A JPS4910958B1 (en) | 1969-11-18 | 1969-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO126085B true NO126085B (en) | 1972-12-18 |
Family
ID=14052400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO4341/70A NO126085B (en) | 1969-11-18 | 1970-11-13 |
Country Status (15)
Country | Link |
---|---|
JP (2) | JPS5010659B1 (en) |
AT (2) | AT300816B (en) |
BE (1) | BE759099A (en) |
CH (2) | CH549588A (en) |
DE (2) | DE2064926A1 (en) |
DK (1) | DK141846B (en) |
ES (1) | ES385641A1 (en) |
FI (1) | FI51701C (en) |
FR (1) | FR2073379B1 (en) |
GB (2) | GB1337736A (en) |
NL (1) | NL167697C (en) |
NO (1) | NO126085B (en) |
SE (1) | SE363111B (en) |
YU (1) | YU34898B (en) |
ZA (1) | ZA707644B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA713364B (en) * | 1970-06-18 | 1972-01-26 | Upjohn Co | Prganic compounds and process |
JPS494470B1 (en) * | 1970-08-26 | 1974-02-01 | ||
CH545302A (en) * | 1971-04-08 | 1974-01-13 | Ciba Geigy Ag | Triazolobenzodiazepine derivs - with anticonvulsant, cns depressant and muscle-relaxant activity |
US3751426A (en) * | 1971-04-28 | 1973-08-07 | Upjohn Co | 1-substituted-6-phenyl-4h-s-triazolo(4,3-a)(1,6)benzodiazepine compounds |
GB1377230A (en) * | 1971-09-13 | 1974-12-11 | Upjohn Co | 4h-s-triazolo -4,3-a- 1,4-benzodiazepines |
BE790356A (en) * | 1971-10-21 | 1973-04-20 | Takeda Chemical Industries Ltd | BENZODIAZEPINE DERIVATIVES |
JPS5418280B2 (en) * | 1971-10-30 | 1979-07-06 | ||
BE793629A (en) * | 1972-01-03 | 1973-07-03 | Upjohn Co | NEW BENZODIAZEPINE DERIVATIVES AND THEIR PREPARATION |
DE3021107A1 (en) * | 1980-06-04 | 1981-12-17 | Hoechst Ag, 6000 Frankfurt | CARBAMOYLOXYAMINO-1,4-BENZODIAZEPINE, METHOD FOR IRER PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THE SAME |
CA1211437A (en) * | 1981-08-12 | 1986-09-16 | Rene Borer | Benzazepines |
CN111533745A (en) * | 2020-05-20 | 2020-08-14 | 成都药明康德新药开发有限公司 | Process for preparing tert-butyl-3- (aminomethyl) dihydro-5H-triazolodiazepine-8 (9H) -carboxylic acid ester |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI50981C (en) * | 1968-11-05 | 1976-09-10 | Takeda Chemical Industries Ltd | Process for the preparation of s-triat solo- (4,3-a) (1,4) -benzodiazepines acting as hypnotics and sedatives. |
US3987052A (en) * | 1969-03-17 | 1976-10-19 | The Upjohn Company | 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines |
-
0
- BE BE759099D patent/BE759099A/en not_active IP Right Cessation
-
1969
- 1969-11-17 JP JP44092336A patent/JPS5010659B1/ja active Pending
- 1969-11-18 JP JP44092366A patent/JPS4910958B1/ja active Pending
-
1970
- 1970-11-11 ZA ZA707644A patent/ZA707644B/en unknown
- 1970-11-13 NO NO4341/70A patent/NO126085B/no unknown
- 1970-11-14 DE DE19702064926 patent/DE2064926A1/en active Pending
- 1970-11-14 DE DE19702056174 patent/DE2056174A1/en active Pending
- 1970-11-17 ES ES385641A patent/ES385641A1/en not_active Expired
- 1970-11-17 NL NL7016848A patent/NL167697C/en not_active IP Right Cessation
- 1970-11-17 FR FR7041215A patent/FR2073379B1/fr not_active Expired
- 1970-11-17 DK DK582970AA patent/DK141846B/en unknown
- 1970-11-18 GB GB5479770A patent/GB1337736A/en not_active Expired
- 1970-11-18 YU YU2827/70A patent/YU34898B/en unknown
- 1970-11-18 CH CH1060273A patent/CH549588A/en not_active IP Right Cessation
- 1970-11-18 SE SE15638/70A patent/SE363111B/xx unknown
- 1970-11-18 AT AT1038070A patent/AT300816B/en not_active IP Right Cessation
- 1970-11-18 FI FI703096A patent/FI51701C/en active
- 1970-11-18 GB GB2860172A patent/GB1337737A/en not_active Expired
- 1970-11-18 AT AT995571A patent/AT311993B/en not_active IP Right Cessation
- 1970-11-18 CH CH1708170A patent/CH551432A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES385641A1 (en) | 1973-10-01 |
DE2064926A1 (en) | 1971-07-22 |
DE2056174A1 (en) | 1971-06-24 |
JPS5010659B1 (en) | 1975-04-23 |
AT311993B (en) | 1973-12-10 |
DK141846C (en) | 1980-11-24 |
GB1337737A (en) | 1973-11-21 |
NL167697C (en) | 1982-01-18 |
BE759099A (en) | 1971-04-30 |
JPS4910958B1 (en) | 1974-03-13 |
SE363111B (en) | 1974-01-07 |
ZA707644B (en) | 1971-08-25 |
AT300816B (en) | 1972-08-10 |
CH551432A (en) | 1974-07-15 |
NL7016848A (en) | 1971-05-21 |
GB1337736A (en) | 1973-11-21 |
FI51701C (en) | 1977-03-10 |
FI51701B (en) | 1976-11-30 |
CH549588A (en) | 1974-05-31 |
DK141846B (en) | 1980-06-30 |
NL167697B (en) | 1981-08-17 |
FR2073379A1 (en) | 1971-10-01 |
FR2073379B1 (en) | 1974-08-23 |
YU34898B (en) | 1980-04-30 |
YU282770A (en) | 1979-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS61165386A (en) | Triazoloquinazoline compound, manufacture and medicinal composition | |
US3763179A (en) | 2-imidazol-1-yl benzophenones | |
US3778433A (en) | Process for producing benzodiazepine derivatives | |
NO126085B (en) | ||
US3818003A (en) | Tricyclic benzodiazepines | |
NO126325B (en) | ||
HU197011B (en) | Process for producing new imidazo- and triazolo-1,4-benzodiazepines and pharmaceuticals comprising the same | |
DE2220623A1 (en) | New 4H-s-Triazolo [4,3-a] [1,4] benzodiazepines | |
NO126799B (en) | ||
US3709899A (en) | 6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepines and their production | |
US3846443A (en) | 1H-IMIDAZO{8 1,2a{9 {8 1,4{9 BENZO-DIAZEPINE-1,2(3H)-DIONES | |
US3903103A (en) | 4-Amino-s-triazolo-{8 4,3-a{9 {8 1,4{9 benzodiazepine | |
US3849405A (en) | Thieno-(2,3-e)(1,4)diazepin-2-ones | |
US4395409A (en) | Carbamoyloxyamino-1,4-benzodiazepines and medicaments containing these compounds | |
US4410698A (en) | Oxadiazolopyrimidine derivatives | |
US3825533A (en) | N-carboxymethyl-n-substituted glycinate esters of 3-hydroxy-1,4-benzo-diazepin-2-ones | |
US4175079A (en) | Benzodiazepine derivatives | |
US4116956A (en) | Benzodiazepine derivatives | |
US3847935A (en) | 5-substituted 1-(3h,1,4-benzodiazepin-2-yl)-2-imidazolidinones | |
US3864356A (en) | Method for preparing S-Triazolo (4,3-A) (1,4) Benzodiazepine Derivatives | |
US3856802A (en) | 1,6-DISUBSTITUTED-4H-5-{8 4,3-a{9 BENZODIAZEPINES | |
US3850951A (en) | Triazolobenzodiazepine 5n-oxide derivatives | |
US3721666A (en) | 1-(phenyl or pyridyl)-4-(alkyl or alkenyl)-3h-1,4-benzodiazepine-2,5-(1h,4h)-diones | |
NO177749B (en) | Analogous Process for Preparation of 2,4,8-Tri-Substituted 3H, 6H-1,4,5a, 8a-Tetraazaacetaphthylene-3,5- (4H) -Diones | |
JPS62135475A (en) | 2-substituted-e-fused-(1, 2, 4) triazolo (1, 5-c) pyrimidine |